论文部分内容阅读
目的 :1 .观察实体瘤化疗周期中预防性应用rhG CSF对中性粒细胞数量减少干预作用的效果。 2 .观察rhG CSF的不良反应。方法 :采用单盲随机、自身交叉对照研究方法 ,对 69例经病理学证实的胃癌等实体瘤患者进行研究 ,在治疗周期 (A周期 )末次化疗给药 48h后 ,按 5μg/kg剂量皮下注射rhG CSF ,每天 1次 ,共用 7～ 1 4d ;隔日查中性粒细胞、白细胞、血红蛋白、血小板数值。结果 :治疗周期中 (A周期 )中性粒细胞绝对值 (ANC)明显高于对照周期 (B周期 ) ,ANC减少持续天数、中性粒细胞减少性发热及抗生素使用频率A周期明显低于B周期 ,有显著性差异 (P <0 .0 5) ;中性粒细胞的双峰分别出现在用rhG CSF后第 4、1 0d ,B周期则无双峰现象。A、B周期中Hb、Plt值无明显差异。不良反应主要是乏力、感冒样症状、骨肌肉疼痛、注射局部反应和发热。结论 :预防性使用rhG CSF能有效地防止中性粒细胞减低、中性粒细胞减少性发热及感染的发生 ,不良反应可以耐受
Objective: 1. To observe the effect of prophylactic rhG CSF on neutrophil count reduction in solid tumor chemotherapy cycles. 2. Observe the adverse reactions of rhG CSF. METHODS: A total of 69 patients with pathologically confirmed solid tumors such as gastric cancer were studied by a single-blind randomized, self-controlled cross-over study. At the end of the treatment cycle (A cycle), 48h after the last chemotherapy, subcutaneous injection rhG CSF once a day, sharing 7 ~ 14d; check neutrophils, leukocytes, hemoglobin, platelet values every other day. Results: The absolute value of neutrophil (ANC) in the treatment cycle (A cycle) was significantly higher than that in the control cycle (B cycle). The duration of ANC decrease, neutropenia fever and antibiotic use frequency A cycle were significantly lower than B Cycle, there was significant difference (P <0.05); bimodal neutrophils appeared in rhG CSF after 4,1 0d, B cycle no double peak phenomenon. A, B cycle Hb, Plt value no significant difference. Adverse reactions are mainly weakness, flu-like symptoms, bone and muscle pain, local injection and fever. Conclusion: Prophylactic rhG CSF can effectively prevent neutropenia, neutropenic fever and infection, and adverse reactions can be tolerated